Sep 01, 2015 08:50 AM EDT
Kim Kardashian's Corrective Ad After FDA Busts Her Morning Sickness Pills

Kim Kardashian, who got slammed by FDA over "false and misleading" endorsement posted corrective ad on her Instagram to comply with the agency's warning.

After receiving FDA's warning, 'The Keeping Up With The Kardashians' star backtracked on her endorsement.

She wrote to her Instagram account, "I guess you saw the attention my last #morningsickness post received."

Then she continued, "The FDA has told Duchesnay Inc. that my last post about Diclegis (doxylamine succinate and pyridoxine HCl) was incomplete because it did not include any risk information or important limitations of use for Diclegis. A link to this information accompanied the post, but this didn't meet FDA requirements. So, I'm re-posting and sharing this important information about Diclegis."

Her ad went on with the possible side effects of the pills, including drowsiness and can  "pass into breast milk" for nursing women.

Last month, the 34 year old reality star took advantage of her fame by promoting and recommending Duchesnay's morning sickness pills, Diclegis.

The 'Keeping Up With The Kardashians' star wrote to her Instagram account, "Have you heard about this? As you guys know my #morningsickness has been pretty bad," it read.

"I tried changing things about my lifestyle, like my diet, but nothing helped, so I talked to my doctor. He prescribed me #Diclegis, and I felt a lot better and most importantly, it's been studied and there was no increased risk to the baby."

However, her post caught FDA's eyes, the agency ordered the company to remove the ad from social media, claiming that Kim's post violated the endorsement rule and her ad is "false and misleading."

In a statement which was posted online, FDA wrote, "Because the violations described above are serious and repeated, we request, further, that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective messages about the issues discussed in this letter to the audience(s) that received the violative promotional materials."

 PREVIOUS POST
NEXT POST